An overview of mechanical circulatory support in single-ventricle patients

Jacob R. Miller¹, Timothy S. Lancaster¹, Connor Callahan², Aaron M. Abarbanell³, Pirooz Eghtesady³

¹Division of Cardiothoracic Surgery, ²Department of Surgery, Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis, MO, USA; ³Section of Pediatric Cardiothoracic Surgery, St. Louis Children's Hospital/Washington University School of Medicine, St. Louis, MO, USA

Contributions: (I) Conception and design: JR Miller, AM Abarbanell, P Eghtesady; (II) Administrative support: AM Abarbanell, P Eghtesady; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: JR Miller, TS Lancaster, C Callahan; (V) Data analysis and interpretation: JR Miller, AM Abarbanell, P Eghtesady; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Pirooz Eghtesady, MD, PhD. Chief of Pediatric Cardiothoracic Surgery, St. Louis Children's Hospital, One Children's Place, Suite 5 South, St. Louis, MO 63110, USA. Email: eghtesadyyp@wustl.edu.

Abstract: The population of people with a single-ventricle is continually increasing due to improvements across the spectrum of medical care. Unfortunately, a proportion of these patients will develop heart failure. Often, for these patients, mechanical circulatory support (MCS) represents the only available treatment option. While single-ventricle patients currently represent a small proportion of the total number of patients who receive MCS, as the single-ventricle patient population increases, this number will increase as well. Outcomes for these complex single-ventricle patients who require MCS has begun to be evaluated. When considering the entire population, survival to hospital discharge is 30–50%, though this must be considered with the significant heterogeneity of the single-ventricle patient population. Patients with a single-ventricle have unique anatomy, mechanisms of failure, indications for MCS and the type of support utilized. This has made the interpretation and the generalizability of the limited available data difficult. It is likely that some subsets will have a significantly worse prognosis and others a better one. Unfortunately, with these limited data, indications of a favorable or poor outcome have not yet been elucidated. Though currently, a database has been constructed to address this issue. While the outcomes for these complex patients is unclear, at least in some situations, they are poor. However, significant advances may provide improvements going forward, including new devices, computer simulations and 3D printed models. The most important factor, however, will be the increased experience gained by the heart failure team to improve patient selection, timing, device and configuration selection and operative approach.

Keywords: Mechanical circulatory support (MCS); ventricular assist device (VAD); single-ventricle; Norwood; Glenn; Fontan; review


doi: 10.21037/tp.2018.03.03

View this article at: http://dx.doi.org/10.21037/tp.2018.03.03

Introduction

Individuals with single-ventricle physiology comprise a complex, and heterogenous, sub-group of patients with congenital heart disease (CHD). Palliation to single-ventricle physiology involves multiple operations eventually resulting in passive blood flow to the pulmonary circulation with the single-ventricle providing systemic blood flow. When cardiac failure develops in these patients, providing mechanical circulatory support (MCS) is an especially challenging problem due to the altered systemic venous return and arterial connections. However, MCS, in the form of extracorporeal membrane oxygenation (ECMO) or a ventricular assist device (VAD), may represent the only alternative to death. While some initial studies have been reported, the outcome of single-ventricle patients who...
require MCS remains unclear.

With improved operative techniques and critical care, the single-ventricle population is continually increasing. Currently, more than 1,000 new Fontan operations are performed annually in the United States and Canada alone (1). The first generation of surviving patients with Fontan physiology are now well into adulthood (2). These numbers include only patients who have reached the Fontan stage, and do not include the single-ventricle patients currently living at an earlier stage of palliation. As the single-ventricle population has increased, heart failure in patients with a single-ventricle has become the most common indication for heart transplant in children (3). Not surprisingly, in correlation, MCS for single-ventricle patients has increased, and is only likely to further increase in the future (4). Currently, nearly half of all pediatric patients who are placed on ECMO for cardiac indications have a single-ventricle (5).

ECMO has been utilized extensively in pediatric patients due to its speed of initiation, ability to provide both cardiac and pulmonary support, ability to support patients of any size (except the smallest of neonates), and the ability to seamlessly transition from cardiopulmonary bypass (CPB). However, survival for patients who require ECMO is poor for patients with CHD, and even worse for patients with a single-ventricle (5). It is employed to allow for myocardial recovery, support until a reparative operation can be performed or (more recently) as a bridge to a VAD, and potentially as a bridge to decision. ECMO, however, is hampered by a significant complication rate that increases with the duration of support (6,7). Currently, VADs have been increasingly utilized in many pediatric situations (8-13). A VAD offers the benefits of a longer duration of support, therefore, allowing more time for either recovery or to find a suitable donor (14). Therefore, ECMO and VAD support should be treated as unique therapies with different indications for use.

Importantly, while patients are often considered within a single category, “single-ventricle”, they can develop cardiac failure at any stage of palliation and at any time postoperatively. Therefore, the term “single-ventricle” encompasses a heterogeneous patient population. Further, the mode of failure is often distinct, within each stage of palliation and for each patient specifically, making each patient with cardiac failure and any form of single-ventricle anatomy truly unique. Lastly, due to the small sample sizes, ECMO and VADs are often considered together as MCS, despite device selection having significant implications on the patient's outcome.

This review focuses on the current utilization of MCS in patients with a single-ventricle. As this is an uncommon indication, and each situation is very unique, the data are limited, as is the generalizability of the published literature. We discuss the overall reported outcomes of MCS in single-ventricle patients, the implications of the varied cardiac anatomy, MCS device chosen, cannulation strategies and technical considerations. Data from the largest existing series is cited whenever possible. Case reports or small series are used as necessary, though, with appropriate consideration of a significant publication bias.

Outcomes

The current data available evaluating the survival of single-ventricle patients who require MCS are quite limited and difficult to interpret. Most consider the survival to hospital discharge of single-ventricle patients who require MCS to be 30–50% (4,15-18). When evaluating all patients with a single-ventricle who underwent MCS over a 25-year period at a single institution, of 57 patients, 18 (33%) survived to hospital discharge (16). Considering the Berlin Heart EXCOR IDE database, evaluating outcomes for single-ventricle patients, survival of 26 patients was 42% (4). Utilizing the KID (Kids Inpatient Database) to analyze survival in single-ventricle patients who require ECMO allowed for an analysis of 701 patients over 10 years; overall survival was 43%, and importantly, the outcomes did not improve over the decade evaluated (15). Though these are the most informative studies available, each evaluated the outcomes of a heterogenous patient population, with unique anatomy and indications for MCS. Definitively, the data does support that single-ventricle patients who require ECMO are likely to have poor outcomes, even worse than other CHDs (4). Additionally, patients who demonstrate any type of end-organ dysfunction prior to MCS initiation are more likely to have a poor outcome (9).

Impact of stage of palliation of single-ventricle physiology

Likely the most important factor impacting the anticipated survival for any patient requiring MCS is the stage of palliation (19). This is for many reasons, first, being that the patient’s current anatomy likely impacts their response to MCS (20). Additionally, stage of palliation correlates with many factors that likely dictate the patient’s outcome including: size, age, available devices, ability to
anticoagulate and availability of donors for transplant. In addition, possibly the most important factor is indication. Clearly a patient who requires ECMO for inability to wean from CPB after Norwood is different than an adult with late Fontan failure who requires VAD as a bridge to transplant.

First stage
Patients who require MCS after the first stage of palliation are often suffering from post-cardiotomy shock. As these patients recover from CPB and adapt to their new circulation, MCS may be necessary as a bridge to recovery. In these patients, the MCS must provide cardiopulmonary support with ECMO or, if only cardiac support, provide sufficient flow through the systemic circulation and the systemic-pulmonary shunt. In the previously referenced studies evaluating the survival for single-ventricle patients who received MCS, survival of patients who required MCS after their first stage were 32% for patients supported with a VAD (16) and 11% when considering the Berlin Heart EXCOR IDE database (4).

Most would expect this patient population to have a poor survival, as it is essentially selected for neonatal post-cardiotomy patients who are unable to tolerate their new circulation. Indeed, the survival for these patients in the reports referenced above is not good. Others, however, have reported over 40% survival with MCS utilization after stage I of palliation (17). Substantially different results may be in part due to device selection, surgical technique or postoperative care, however, patient selection is by far the most likely factor. Supporting this, when utilized on patients who have a repairable problem (usually shunt thrombosis), when MCS support is required between stages I and II, survival greater than 80% is reported (18). Further, when VAD implantation is utilized after every Norwood, even in patients who are stable, survival approaches 90% (21). Though some might state this as evidence for the routine use of MCS after Norwood, much more likely, it demonstrates the impact of patient selection. Whether indiscriminate use of MCS would improve overall survival by providing early assistance to the most difficult patients, remains to be seen.

An additional consideration for post-Norwood patients is the type of systemic-pulmonary shunt, Blalock-Taussig (BT) or Sano. Though it has never been studied, the type of systemic-pulmonary shunt will influence outcomes of patients after stage I who require MCS. With a Sano shunt, flow through the pulmonary circulation is dependent on blood within the failing ventricle, which is diminished in a ventricle that is decompressed. We have typically taken down the Sano shunt and created a BT shunt at the time of VAD implant; or, on occasion, we have disconnected the proximal aspect of the Sano and reattached it to the outflow graft of the VAD (Figure 1) (22).

Second stage
MCS after the second stage of palliation has the advantage of a more efficient anatomy than a Norwood, due to the superior cavopulmonary connection (SCPC) supplying the pulmonary vasculature in series with the systemic circulation (Figure 2). However, with only a SCPC, the decompression of the single-ventricle has competing implications. Both the VAD augmented cardiac output and ventricular decompression act to increase flow through the Glenn anastomosis and improve oxygenation. Conversely, there will also be an increased flow of deoxygenated blood through the inferior vena cava (IVC). The summation has been shown in an experimental model to lead to increased oxygen delivery (23). Additionally, in case reports, it leads to improved hemodynamics (24,25). MCS use after the second stage, when considering the previously discussed manuscripts, has a survival of 36% for all VADs (16) and 58% when looking at the Berlin Heart EXCOR IDE database (4). These are both very small patient populations, 11 and 26, respectively.
Some institutions, feel that patients who deteriorate shortly after Glenn are demonstrating their inability to tolerate the circulation and that they warrant consideration of SCPC takedown and recreation of the systemic-pulmonary shunt while implanting the VAD (16). These sentiments are based on poor outcomes with attempts at VAD support immediately post SCPC. Importantly, implantation of MCS on the systemic side would not address underlying problems with pulmonary vasculature or other limitations to pulmonary blood flow that are not related to sufficient cardiac output. These patients would subsequently require a heart transplant. As much as any, the patients who require MCS after SCPC have outcomes that remain unknown.

Third stage
For patients with a failing Fontan, when taken as a whole, the previously referenced studies noted survival to hospital discharge of 40% for any VAD (16) and 60% when considering the Berlin Heart EXCOR IDE database (4). Inflow cannulation can be performed via the ventricular apex (Figure 3A) or the atrium (Figure 3B). The outcomes for patients with a failed Fontan must be considered based on indication for VAD implant. Certainly, those with early Fontan failure are a different patient population than those with late Fontan failure. Further, in patients with late Fontan failure, the indication for VAD can be either impaired ventricular function (IVF) or preserved ventricular function (PVF) but with failing Fontan physiology.

Heart failure in the acute postoperative period after Fontan has been successfully supported with MCS in multiple instances. Some are for patients in the acute postoperative Fontan period (26), others for Fontan patients who required additional cardiac operations and developed

Figure 2 Cannulation after stage II of palliation. Similar cannulas are utilized as after stage I. The superior cavopulmonary anastomosis is demonstrated and the systemic-pulmonary shunt has been taken down.

Figure 3 HeartWare HVAD placement in patients with a failing Fontan. (A) The HVAD inflow cannula is placed within the ventricular apex with the outflow cannula into the neoartery; (B) the HVAD inflow cannula is placed into the atrium with the outflow cannula into the neoartery.
postcardiotomy shock (27,28). There have been reports of successful bridge to recovery postoperatively, after even long durations of VAD support (29).

For late failing Fontan, indications typically fall on the spectrum between IVF and PVF. Considering VAD implant for these two indications, it is unlikely they would have similar outcomes with the same support. Patients with IVF would be expected to benefit quickly from a VAD implanted to support the systemic ventricle, whereas those with a predominately failing physiology may take significantly more time to recover. This is what was initially seen with heart transplant for failing Fontan, the outcomes for patients with IVF were initially superior (30). Though, with improved preoperative care, operative techniques and postoperative care, it has now been shown that survival after heart transplant may now be equivalent (31,32). It has been argued that a patient with IVF would do very well with a single VAD supporting the systemic circulation, whereas a patient with predominately PVF may require support of both sides of the circulation, either with two VADs or a total artificial heart (TAH). There is insufficient data at this point to argue either against or for such approaches; further, few patients present with discrete phenotypes of one or the other, with significant overlap in most.

These patients who survive into adolescence or adulthood but subsequently develop late Fontan failure comprise a group that should be expected to have a high rate of survival. Indeed, many reports exist demonstrating survival to transplant for both PVF (33,34) and IVF (35). Considering that the vast majority are case reports, a substantial publication bias probably gives a false impression of the success rate. Likely one of the main factors leading to poor outcomes is the reluctance of the heart failure team to pursue VAD implant, either due to unfamiliarity of the anatomy or acknowledgement of the increased risk associated with the procedure (14). So when MCS is finally initiated, the patient is more debilitated than a traditional patient who requires VAD implant. Importantly, late failing Fontans are a group of patients which will only increase. Though the operations for this patient population are quite difficult, with appropriate patient selection and timing, outcomes should be expected to be quite high.

**Device type**

Currently, many devices are available to support patients with heart failure. The device chosen depends on many factors including the indication [anticipated recovery or bridge to transplant (BTT)], pulmonary function, anatomy and size. In addition, if utilized as a BTT, the anticipated duration on the waiting-list is an important factor and, therefore, additional factors must be considered such as antibody status.

ECMO is the first established MCS. Being comprised of both a pump and an oxygenator, it has long been utilized to treat patients with cardiorespiratory failure. It remains very useful for multiple indications, mainly for its ease and speed in initiation/cannulation and termination/decanulation. It can be initiated using the internal jugular and carotid in young children or the femoral artery and vein in larger children and adults, or centrally via median sternotomy. Additionally, transition from CPB to ECMO is quite easy. It does, however, have a significant risk profile, with a serious risk of adverse events with any significant duration. Due to these attributes it is ideally suited for emergencies or support that is anticipated to be of short duration (6,7). Limitations of ECMO stem in part from the typical required approach: peripheral cannulation generally limits flow rates (in contrast to central cannulation) due to vessel size, increased surface exposure from long segments of an intravascular cannula (and hence greater chance for activation of clotting cascades as well as the need for anticoagulation), and inherent limitations of mobility and rehabilitation potential related to concerns with cannula dislodgment. Otherwise ECMO circuitry can be quite similar to those commonly used in the pediatric setting with temporary devices (see below) with the added oxygenator.

Many pediatric VADs are simply ECMO without the oxygenator, such as a CentriMag or PediMag [St. Jude Medical Inc. (Thoratec), St. Paul, MN, USA]. Though still hampered by many of the disadvantages of ECMO, most feel they are far better tolerated with a lower risk of adverse events with a longer duration. Patients who have undergone an operation may require transition from CPB to a VAD of this type for a short period of time to allow for recovery from the stress of an operation as well as the adaptation to new anatomy (21). Additionally, for patients who initially came off bypass, but then developed progressively worsening failure, VAD support may prove necessary in the acute postoperative period, potentially urgently. ECMO or an extracorporeal VAD is ideally suited for these indications.

For longer-term support, a different set of devices has emerged as the choice whenever possible. These include the Berlin Heart EXCOR (EXCOR) (Berlin Heart, GmbH, Berlin, Germany), the HeartMate II (HMII) [St. Jude Medical Inc. (Thoratec), St. Paul, MN, USA] and the
HeartWare HVAD (HVAD) (HeartWare International, Framingham, MA, USA). The EXCOR has shown significant utility in pediatric patients in nearly all settings, including patients with a single-ventricle (4,9,11,36-38). The EXCOR is an extracorporeal pneumatically driven pulsatile device with a large controller tower. The HM II and the HVAD are much smaller intracorporeal continuous-flow (CF) devices with easily transported battery packs. These CF devices, while originally designed for adults, have been used extensively in pediatrics (39,40). Their use in patients with a single-ventricle remains quite limited, though there are case reports (33-35). In pediatric patients, practice has recently shifted to CF devices in patients large enough to support one (41). The CF design allows for a smaller device, which allows for improved patient mobility and rehabilitation. Going forward, the majority of devices placed in patients of sufficient size will be a CF device.

While not as commonly utilized, some report excellent experiences with the Syncardia Total Artificial Heart (Syncardia Systems, Tucson, AZ, USA) in pediatric patients, and its use has been described in a single-ventricle patient (42,43). In a patient with a failing single-ventricle, most specifically with failing physiology or a mixed picture, it may prove to have significant utility. Theoretically, it could allow for the advantages of BiVAD support with improved rehabilitation due to the increased mobility over two devices. Indeed, its use has been described successfully in a patient with failing Fontan physiology (43).

We advocate for the use of an intracorporeal VAD whenever possible, for multiple reasons including, the demonstrated improved outcomes in other populations, the improved ability for rehabilitation and the improved quality of life (8,9,11,16,44). The Berlin Heart EXCOR may be necessary if the patient is small, but if the patient is large enough [body surface area (BSA) is >1 m²], a CF VAD should be used. We prefer the HeartWare HVAD due to its size. In the patient who is acutely postoperative, either unable to wean from bypass or deteriorates in the acute postoperative period, we recommend transition from CPB to ECMO or VAD such as the PediMag (depending on pulmonary function). If postoperative failure develops suddenly and requires urgent MCS, ECMO should be initiated peripherally. However, once it is determined that there is no pulmonary pathology, the patient should be converted to a VAD to allow for recovery or BTT. Specifically, we attempt to avoid the use of an oxygenator whenever possible (45).

### Configuration

When utilizing MCS in a patient with a single-ventricle, the patient’s anatomy and pathology must both be considered so that the MCS is used optimally. Patients with a single-ventricle fail due to failure of the ventricle to support the systemic circulation (or systemic and pulmonary in a shunted patient), or due to their inability to tolerate their passive pulmonary circulation. Therefore, the selection of the device configuration is likely the most important controllable factor, with the exception of whether or not to utilize MCS at all. Multiple configurations are possible, systemic VAD placement, VAD support for only the pulmonary circulation and BiVAD or TAH support, all of which have been described.

When supporting patients after stage 1 of palliation, the device must provide flow to support both the systemic and pulmonary circulation. We have recently come to prefer a cannulation technique which utilizes the common atrium for inflow and the neoaorta as outflow (22). In our experience, we have found cannula selection to be very important in limiting thrombus formation. For the inflow, we prefer the arterial Berlin Heart cannula due to its smaller surface within the atrium and lower likelihood of creating stagnant flow. The outflow cannula is the Berlin Heart aortic cannula with either a homograft or Gore-Tex (W.L. Gore and Associates, Elkton, MD, USA) extension. If the patient has a Sano shunt, this is taken down. To provide pulmonary flow, either a BT shunt is created or the proximal end of the Sano shunt is anastomosed end-to-side to the outflow cannula via the homograft or Gore-Tex extension (45).

For patients after Fontan, the vast majority of patients who receive VAD support, receive support of the systemic ventricle. In a patient with IVF without other signs of failure, this is the ideal treatment option. However, for patients with failing physiology, or a more mixed picture, the decision is more difficult. Our bias is that a single VAD supporting the systemic ventricle will allow for improved physiology as we believe all of these patients suffer from a substantial, and under-appreciated, collateral burden that “steals” 20–50% of cardiac output (and in turn an increased volume load that burdens the single ventricle), in addition to addressing any other underlying pulmonary circulation issues, despite absence of hemodynamic significance (i.e., if there is no gradient by angiography demonstrates suboptimal anatomy). We do not believe that pulmonary blood flow can be augmented by “sucking” it across the pulmonary vascular bed. A decrease in central venous...
pressure upon initiation of inotropic support demonstrates the potential benefit of a VAD for these patients. Some have argued that support of both the systemic ventricle and the right side may be superior, especially if the elevated pulmonary pressures are thought unlikely to be “reversible”. It is hard to believe that these same patients, not too long ago, were deemed to have low enough pulmonary pressures to undergo Fontan palliation. Nevertheless, it has been shown that a single right sided VAD may be sufficient for some patients (46). However, placement of a right sided VAD may be technically quite challenging.

BiVAD support has been described in the failing Fontan patient (47). Though some feel that the addition of a second VAD increases the risk of complications, it has been shown that BiVAD support can be done without increased risk (9,11,48). Implantation of a second pump does, however, increase the surgical complexity of an already difficult operation. Further, the disadvantage of impaired rehabilitation due to a second device may have significant implications. Though, if necessary, not providing support for the pulmonary circulation would leave the patient debilitated, clearly a worse alternative.

Technical difficulties

Utilization of MCS in patients with a single-ventricle is a surgical challenge. These patients require a redo-sternotomy, often times multiple, with what can be a difficult dissection. Patients often have foreign material present, either a Fontan conduit or a systemic-pulmonary shunt. Injury to any native or foreign structures may have catastrophic implications. Further, if a cardiac chamber is inadvertently entered during dissection prior to cross-clamp application, an air embolism is possible. In addition, these patients commonly have substantial collateral flow, which can complicate the dissection prior to CPB and impair visualization once on bypass. Regardless of the configuration of VAD support chosen, sternal entry and the dissection process may be difficult in these patients. For that reason, in our population of multiple redo-sternotomies a femoral arterial and venous line are placed prior to incision. These lines are large enough to accept a wire for percutaneous CPB initiation if it becomes emergently necessary.

For patients who are going to have a VAD implanted, inflow cannula placement is more complex than in a normal ventricle. The inflow can be placed in either the apex of the ventricle or the atrium. Placement within the apex is more familiar to most surgeons but may require significant trabecular resection. Atrial placement avoids the difficulties with trabeculations, but the inherent lack of strength in the atrial wall does create concerns for suck down events. Single-ventricle patients may have a single right ventricle, which will undoubtedly have more-dense trabeculations than a single left ventricle. Further, as the ventricle dilates, the apex can be displaced, making it difficult to identify. As the geometry of the single-ventricle dilates and changes, the angle of the inflow cannula may be difficult to predict. There have been multiple reports of VAD implants into the systemic right ventricle of patients with dextro-transposition of the great arteries (D-TGA) after atrial switch (49-51) or in congenitally corrected TGA (CC-TGA) (52-54). In many, apical inflow cannula placement is aided by use of a needle with transesophageal echocardiographic guidance (55-57). This will allow the cannula to be far enough from the septum and atrioventricular valve to avoid suck down events. In pediatric patients, especially if the ventricular muscle is thinned, the depth of the inflow cannula can be decreased by placing multiple felt rings on the epicardium (35). This latter approach has also been taken with cannulation of the common atrium using the HVAD, successfully bridging Fontan patients to transplant (58).

For patients who do require right sided support, usually, significant surgical reconstruction is necessary; a capacitance chamber may need to be constructed to accommodate the inflow cannula. This chamber must be created from the already surgically manipulated superior vena cava (SVC) and IVC. Outflow cannula placement is into the pulmonary arteries, which also require reconstruction. This significantly increases the operative and bypass time and the surgical risk. As an alternative to BiVAD support, a TAH can be utilized. In this instance, the operative difficulty revolves around returning the systemic venous return to the right atrium, which may need reconstruction, again a major operation (43).

Future directions

ECMO utilization has been shown to be increasing as a percentage of hospitalizations for patients with a single-ventricle (4). In addition, the population of patients who exist with a single-ventricle is continuing to increase. Knowing that a certain percentage of these Fontan patients will eventual fail means that, going forward, an increasing number of VADs will be implanted in patients with a single-ventricle. As many of these will be placed as a BTT, improved timing and patient selection of VAD implantation will become crucial. To accomplish this, risk factors for a
poor outcome need to be more clearly delineated. To that end, a registry was created to identify the risk factors and evaluate the outcomes of patients with a single-ventricle who require MCS (59).

For these complicated patients, going forward, computer models have been developed (60). Using computer models, a simulator has been created to allow for the simulation of a surgical procedure to evaluate the impact of operations at all three stages of palliation (61). These, and other, computer models can be used to demonstrate the impact of MCS utilization in patients with different anatomy (20). As the number of patients treated increases, these models could potentially become more accurate and robust. Theoretically, these could be used to simulate different devices placed in different configurations. This could have a significant impact on preoperative planning.

In patients with single-ventricle and other complex CHDs, three-dimensional (3D) printing has been utilized in some of the most difficult scenarios (62,63). It provides the spatial orientation to potentially improve preoperative planning. Further, it is a useful tool to aid communication with the patient and family, cardiologists and critical care team (64). It has shown utility in allowing for preoperative planning of inflow cannula placement when faced with the challenges of implanting a VAD into a systemic right ventricle (65). Going forward, it may be utilized with more frequency with these complex cases.

For Fontan patients, a unique device has been proposed, and tested in an animal model, a viscous impeller pump (VIP) (66). This device is inserted transvenous and is placed at the junction of the SVC/IVC and PAs (67). As the device rotates, the right sided pressure is augmented and cardiac output is improved (68). It could be used in the failing Fontan, specifically for patients with failing physiology. This could provide temporary support to improve the end-organ function in a patient prior to transplant (69). Further, it could improve patient selection by identifying those who recover end-organ function, presumably a marker for a good outcome post-heart transplant. Currently the use of this device is preclinical.

There are new devices on the horizon in the adult population that could be brought into the pediatric realm. Recently the relatively new HeartMate 3 device [St. Jude Medical Inc. (Thoratec)] has shown promise, with improved 6-month outcomes compared to the HM II, and has a size more comparable to the HVAD (70). The HeartWare MVAD is another device that initially showed promise, especially with its very small size, however, it is not yet available. Finally, the PumpKIN trial continues testing of the Jarvik 2015, a CF device which could support even the smallest of patients (71).

Certainly, in all centers where MCS is utilized in patients with a single-ventricle (either pediatric or adult), experts in every field must be readily available. Others have noted the benefits of a multidisciplinary approach consisting of surgeons and heart failure specialists, intensivists, hematologists, pharmacists, nurses and potentially psychiatrists and infectious disease physicians (72). We feel this is absolutely necessary to optimize the outcomes of these very difficult patients.

Conclusions

Patients with a single-ventricle comprise a heterogenous and inherently difficult patient population. When their condition necessitates the initiation of MCS, currently, their outcome is difficult to predict. Further studies are needed evaluating unique cannulation strategies, outcomes based on stage of palliation, patient selection and timing of MCS. A registry has been created to aid in answering these questions in the future (59).

The number of single-ventricle patients who require MCS is going to increase as the overall single-ventricle population increases. As patients with a failing single-ventricle age and an inevitable portion develops heart failure, some have dubbed a heart transplant the “fourth stage” (73). Likely, many of these patients will be considered at some point for possible VAD support. Though currently the outcomes are poor, there is promise, that with improved devices, increased experience and the development of risk factors to improve patient selection and operative timing, that outcomes will improve significantly.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

1. Jacobs JP, Maruszewski B. Functionally univentricular heart and the fontan operation: lessons learned about patterns of


References
with secondary pulmonary hypertension: mechanical assist device to achieve reverse pulmonary vascular remodelling for subsequent heart transplantation. Heart 2010;96:1164.


58. Mascio CE, Malankar DP, Rome JJ. HeartWare Ventricular Assist Device as a Bridge-to-Transplant in a Small Boy with Complicated Kawasaki Disease. ASAIO J 2017. [Epub ahead of print].


Cite this article as: Miller JR, Lancaster TS, Callahan C, Abarbanell AM, Eghtesady P. An overview of mechanical circulatory support in single-ventricle patients. Transl Pediatr 2018;7(2):151-161. doi: 10.21037/tp.2018.03.03